Principal Financial Group Inc. raised its position in shares of Insmed Incorporated (NASDAQ:INSM – Get Rating) by 30.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,044,748 shares of the biopharmaceutical company’s stock after acquiring an additional 242,612 shares during the quarter. Principal Financial Group Inc.’s holdings in Insmed were worth $20,602,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of INSM. Nisa Investment Advisors LLC raised its holdings in shares of Insmed by 38.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,015 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 1,110 shares during the period. Point72 Hong Kong Ltd raised its holdings in shares of Insmed by 270.1% during the first quarter. Point72 Hong Kong Ltd now owns 6,177 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 4,508 shares during the period. OLD National Bancorp IN acquired a new position in shares of Insmed during the second quarter valued at about $205,000. Duality Advisers LP acquired a new position in shares of Insmed during the first quarter valued at about $209,000. Finally, Cetera Advisor Networks LLC raised its holdings in shares of Insmed by 15.1% during the first quarter. Cetera Advisor Networks LLC now owns 11,405 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 1,500 shares during the period.
Insider Buying and Selling at Insmed
In related news, Director Melvin Md Sharoky bought 20,000 shares of Insmed stock in a transaction dated Monday, October 31st. The stock was purchased at an average cost of $17.53 per share, with a total value of $350,600.00. Following the transaction, the director now directly owns 281,021 shares of the company’s stock, valued at $4,926,298.13. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.40% of the company’s stock.
Analyst Upgrades and Downgrades
Insmed Trading Down 2.9 %
NASDAQ:INSM opened at $18.93 on Tuesday. The company has a debt-to-equity ratio of 18.24, a quick ratio of 4.11 and a current ratio of 4.59. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -5.20 and a beta of 1.58. Insmed Incorporated has a 52 week low of $16.41 and a 52 week high of $30.96. The firm has a 50-day moving average price of $20.38 and a two-hundred day moving average price of $21.45.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.